SEHK:6990Biotechs
Should Kelun-Biotech’s MediLink Settlement and 2026 Framework Deals Reshape SEHK:6990’s Operating Playbook?
Sichuan Kelun-Biotech Biopharmaceutical has called an extraordinary general meeting for 31 December 2025 to approve several 2026 framework agreements covering promotional services, auxiliary R&D support, and procurement and sale of equipment and materials, while also settling trade secret and civil litigation disputes with MediLink Therapeutics through a profit- and income-sharing arrangement.
By simultaneously formalising future operating relationships and removing legal uncertainty via the...